Abstract:min, respectively, prior to aldicarb (0.4 mg/kg), provided complete protection. Therapeutic administration of these two antidotes in combination also completely reversed the clinical signs of intoxication. It is suggested that memantine antagonized the aldicarb acute toxicity by protection/reactivation of activities of AChE and CarbE and reversible blockade of hyperneuromuscular transmission, in addition to muscarinic ACh receptor blockade by atropine.
“…These findings are further strengthened by the recent observations with rivastigmine in in vitro and in vivo studies [Enz and Gentsch, 2004]. However, numerous in vivo studies have demonstrated that at higher doses MEM attenuates AChE inhibition against several organophosphate (OP) nerve agents (soman, sarin, tabun, and VX), an OP prototype compound (DFP) and an insecticide (methyl parathion), and carbamate insecticides (carbofuran, aldicarb, oxamyl, and methomyl) [Gupta and Kadel, 1989, 1990, 1991Gupta and Dettbarn, 1992;McLean et al, 1992;Gupta, 1994;Gupta and Goad, 2000]. Both in vitro and in vivo studies [McLean et al, 1992;Stojiljkovic et al, 2002;Antonijevic et al, 2002] further confirmed that MEM pretreatment protects AChE in rat and mice brain against soman-induced AChE inhibition.…”
Section: Discussionmentioning
confidence: 64%
“…Memantine (MEM) is a specific, uncompetitive, voltage-dependent NMDA receptor antagonist with low-to moderate-affinity, strong voltage dependency, and rapid blocking/unblocking receptor kinetics and is effective in moderate to severe cases of dementia Reisberg et al, 2003;Wilcock, 2003]. Numerous data demonstrate that at higher doses, MEM induced attenuation of in vitro/in vivo AChE inhibition by organophosphates and carbamates [Gupta and Kadel, 1989, 1990, 1991Gupta and Dettbarn, 1992;McLean et al, 1992;Gupta, 1994]. In an in vitro study, Wenk et al [2000] found no interaction of MEM with AChE inhibitors, including donepezil, tacrine, and galantamine.…”
This in vivo study investigated whether the N-methyl-D-aspartate receptor antagonist, memantine (MEM), interacts with inhibition of acetylcholinesterase (AChE) by reversible (donepezil and rivastigmine) and irreversible (diisopropyl fluorophosphate (DFP) and metrifonate) AChE inhibitors (AChEIs) in rat brain regions (cortex and hippocampus), which are affected in humans with Alzheimer's disease. MEM (10 mg/kg, e.g., two to four times greater than the therapeutically relevant dose) was administered 15 min prior to donepezil (0.75 or 1.5 mg/kg), rivastigmine (0.35 or 0.7 mg/kg), metrifonate (55 or 110 mg/kg), or DFP (1.5 or 3.0 mg/kg). DFP was used as positive control. Rats were sacrificed at the time of maximal AChE inhibition (determined from time course studies; 15 min after donepezil, 30 min after rivastigmine or metrifonate, 60 min after DFP) to determine AChE activity in the brain region homogenates. Neither MEM nor AChEIs produced any behavioral effects at any time during the study, except metrifonate, which produced muscle tremors and fasciculations at 110 mg/kg. The present studies showed that i) MEM itself did not inhibit AChE in any brain area; ii) MEM did not interact with AChE inhibition induced by therapeutically used AChEIs (donepezil and rivastigmine) at either dose level; iii) MEM prevented AChE inhibition caused by DFP or metrifonate; and (iv) MEM prevented metrifonateinduced tremors and fasciculations. These findings indicate that MEM does not influence AChE inhibition by donepezil or rivastigmine, and therefore the possibility exists that either of the two antidementic drugs can be used concurrently with MEM. Drug Dev. Res. 64:71-81, 2005.
“…These findings are further strengthened by the recent observations with rivastigmine in in vitro and in vivo studies [Enz and Gentsch, 2004]. However, numerous in vivo studies have demonstrated that at higher doses MEM attenuates AChE inhibition against several organophosphate (OP) nerve agents (soman, sarin, tabun, and VX), an OP prototype compound (DFP) and an insecticide (methyl parathion), and carbamate insecticides (carbofuran, aldicarb, oxamyl, and methomyl) [Gupta and Kadel, 1989, 1990, 1991Gupta and Dettbarn, 1992;McLean et al, 1992;Gupta, 1994;Gupta and Goad, 2000]. Both in vitro and in vivo studies [McLean et al, 1992;Stojiljkovic et al, 2002;Antonijevic et al, 2002] further confirmed that MEM pretreatment protects AChE in rat and mice brain against soman-induced AChE inhibition.…”
Section: Discussionmentioning
confidence: 64%
“…Memantine (MEM) is a specific, uncompetitive, voltage-dependent NMDA receptor antagonist with low-to moderate-affinity, strong voltage dependency, and rapid blocking/unblocking receptor kinetics and is effective in moderate to severe cases of dementia Reisberg et al, 2003;Wilcock, 2003]. Numerous data demonstrate that at higher doses, MEM induced attenuation of in vitro/in vivo AChE inhibition by organophosphates and carbamates [Gupta and Kadel, 1989, 1990, 1991Gupta and Dettbarn, 1992;McLean et al, 1992;Gupta, 1994]. In an in vitro study, Wenk et al [2000] found no interaction of MEM with AChE inhibitors, including donepezil, tacrine, and galantamine.…”
This in vivo study investigated whether the N-methyl-D-aspartate receptor antagonist, memantine (MEM), interacts with inhibition of acetylcholinesterase (AChE) by reversible (donepezil and rivastigmine) and irreversible (diisopropyl fluorophosphate (DFP) and metrifonate) AChE inhibitors (AChEIs) in rat brain regions (cortex and hippocampus), which are affected in humans with Alzheimer's disease. MEM (10 mg/kg, e.g., two to four times greater than the therapeutically relevant dose) was administered 15 min prior to donepezil (0.75 or 1.5 mg/kg), rivastigmine (0.35 or 0.7 mg/kg), metrifonate (55 or 110 mg/kg), or DFP (1.5 or 3.0 mg/kg). DFP was used as positive control. Rats were sacrificed at the time of maximal AChE inhibition (determined from time course studies; 15 min after donepezil, 30 min after rivastigmine or metrifonate, 60 min after DFP) to determine AChE activity in the brain region homogenates. Neither MEM nor AChEIs produced any behavioral effects at any time during the study, except metrifonate, which produced muscle tremors and fasciculations at 110 mg/kg. The present studies showed that i) MEM itself did not inhibit AChE in any brain area; ii) MEM did not interact with AChE inhibition induced by therapeutically used AChEIs (donepezil and rivastigmine) at either dose level; iii) MEM prevented AChE inhibition caused by DFP or metrifonate; and (iv) MEM prevented metrifonateinduced tremors and fasciculations. These findings indicate that MEM does not influence AChE inhibition by donepezil or rivastigmine, and therefore the possibility exists that either of the two antidementic drugs can be used concurrently with MEM. Drug Dev. Res. 64:71-81, 2005.
“…In contrast to the organophosphates, recovery of AChE activity after a carbamate (e.g., carbofuran)-induced inhibition is quite rapid since recovery simply requires the spontaneous hydrolysis of the covalent bond between the methyl carbamyl moiety and the enzyme (Ferguson et al, 1984;Gupta and Kadel, 1989). This observation is also true for several other carbamate pesticides, including aldicarb, methomyl, and propoxur (Gupta, 1994(Gupta, , 2004Gupta and Kadel, 1990, 1991a, 1991b.…”
Section: Effects Of Organophosphates and Carbamates On Acetylcholinesmentioning
confidence: 80%
“…These authors suggested that mAChRs and nAChRs, as well as NMDA receptors, seem to play major roles in anticholinesterase-induced neurotoxicity and that combined treatment with cholinergic and NMDA antagonists might be beneficial in anticholinesterase-induced poisonings (Dekundy et al, 2001(Dekundy et al, , 2003. In similar studies, another NMDA receptor antagonist memantine, in combination with atropine, has been found equally effective against organophosphate and carbamate poisoning (Gupta, 1994;Gupta and Kadel, 1989, 1990, 1991a, 1991bMcLean et al, 1992).…”
Section: Effects On Neuroactivities Other Than the Cholinergic Systemmentioning
“…Tom prilikom saopšteno je i da predtretman memantinom smanjuje stepen inhibicije AChE raznih regija mozga i nekih skeletnih mišića kod pacova trovanih somanom. Od strane istih istraživača, usledila su ubrzo i ispitivanja profilaktičkog i terapijskog efekta memantina i atropina kod većeg broja antiholinesteraznih supstanci [26][27][28][29][30][31][32][33][34] .…”
Memantine potentiated the antidotal effect of HI-6 against a lethal dose of soman, as well as the ability of obidoxime to antagonize the toxic effects of dichlorvos and heptenophos probably partly due to its anticonvulsive properties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.